Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL PD 1 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus EXTRANEAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIANEAL PD 1 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus EXTRANEAL.
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER vs EXTRANEAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dianeal PD-1 with dextrose 3.5% is a peritoneal dialysis solution that uses dextrose as an osmotic agent to create an osmotic gradient across the peritoneal membrane, facilitating the removal of waste products (urea, creatinine) and excess fluid from the blood into the dialysate.
Extraneal (icodextrin) is a glucose polymer that acts as an osmotic agent for peritoneal dialysis. It is absorbed from the peritoneal cavity into the bloodstream and metabolized to maltose and other oligosaccharides. Its primary mechanism is to create an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and removal of waste products.
2-3 L intraperitoneally, dwell time 4-6 hours, 4-5 exchanges per day
7.5% solution: 2 L intraperitoneally, dwell time 4–8 hours, up to 4 exchanges per day. For automated peritoneal dialysis: 2 L per cycle, typically 3–5 cycles overnight.
None Documented
None Documented
Glucose: 1.5–2 hours (intraperitoneal administration leading to systemic absorption); clinical context: prolonged in renal impairment due to decreased clearance of metabolic products, but glucose itself is rapidly metabolized.
The terminal elimination half-life of icodextrin in plasma is approximately 19 hours (range 12-22 hours) following intraperitoneal administration for a dwell of 8-12 hours. This long half-life reflects slow metabolism and clearance, particularly relevant in patients with impaired renal function, leading to accumulation of maltose and other oligosaccharides.
Renal (virtually 100% of absorbed dextrose and metabolites); peritoneal dialysis removes glucose and metabolic byproducts, but significant elimination occurs via transperitoneal absorption into systemic circulation followed by renal excretion (in patients with residual renal function). In anuric patients, glucose is metabolized and eliminated as CO2 and water, with minimal direct excretion.
Icodextrin is metabolized to maltose, maltotriose, and other oligosaccharides. After intraperitoneal administration, approximately 40% of the administered dose is absorbed systemically; the absorbed icodextrin and its metabolites are primarily eliminated by renal excretion (via glomerular filtration). In patients with residual renal function, approximately 30-40% of the absorbed dose is excreted in urine over 14 days. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution